BresaGen (ASX:BGN) is likely to become a holding company with stakes in several businesses, including a new stem cell company formed by the merger of BresaGen's cell therapy division with San Diego stem cell company CyThera, CEO John Smeaton told the company's AGM yesterday. [ + ]

Norwood Abbey (ASX:NAL) executive chairman Peter Hansen told shareholders at the company's AGM yesterday that the first revenues from the company's laser assisted drug delivery device would flow into the company in late December or early January. [ + ]

AgGenomics, a joint venture company owned by Melbourne-based Genetic Technologies (ASX:GTG) and the Victorian government, has been selected as the exclusive Australian provider of DNA profiling services for the selection of A2 dairy cattle for New Zealand company A2 Corporation. [ + ]

Monash University and big German pharmaceutical company Schering AG have announced a collaborative research and licensing agreement to develop new therapies for prostate disease, male infertility, and new male contraceptives. [ + ]

The Peter MacCallum Cancer Centre has spun out its cellular therapies services into a small company called Cell Therapies, in order to make the most of its TGA-licensed Centre for Blood Cell Therapies. [ + ]

Members of South Australia's BioAngels have made their first investment into the South Australian bioscience sector, selecting Australian Orthopaedic Innovations from more than 20 applications. [ + ]

Queensland's reputation as a hub for scientific innovation will be further enhanced next year when work begins on the $60 million Australian Institute of Bioengineering and Nanotechnology (AIBN) complex at The University of Queensland.

Diagnostics company Rockeby Biomed is readying itself to float on the ASX in a back door listing through Carbine Corporation. [ + ]

Perth-based nanomaterials specialist pSivida (ASX:PSD) has acquired the rights to use porous silicon mirror technology from German research agency Forschungszentrum Julich. [ + ]

BresaGen (ASX:BGN) has assigned its cell delivery catheter licenses to North American company NexGen Technologies for about $380,000 plus a four per cent share in NexGen. [ + ]

Melbourne biotechnology company BioDiem has lodged a prospectus with ASIC for an AUD$10 million float opening on December 4. [ + ]

Phenomix, based jointly in San Diego and Canberra, has appointed experienced biotechnology executive Dr Julie Cherrington as president of operations to oversee its Australian activities as it moves into pre-clinical and clinical programs. [ + ]

Cochlear has named ResMed executive VP Dr Chris Roberts as its new CEO, replacing Jack O'Mahony. [ + ]

Adelaide is set to become the leading site for the co-ordination of drug and alcohol research and training in the Asia-Pacific region.

Sydney-based medical device firm Polartechnics (ASX:PLT) has used a combination of a share placement and a share purchase plan to raise AUD$11.25 million to expand its global sales and marketing efforts and refine its production processes. [ + ]